Carlsmed (CARL) Research & Development (2024 - 2026)

Carlsmed (CARL) has reported Research & Development for 3 consecutive years, with $11.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development rose 51.48% year-over-year to $11.9 million; the trailing twelve-month figure through Jun 2026 stood at $42.6 million (up 54.42% YoY), and the FY2025 full-year result was $35.0 million, up 63.13% from the prior year.
• Research & Development rose to $11.9 million in Q2 2026 per CARL's latest filing, from $10.3 million in the prior quarter.
• Across five years, Research & Development topped out at $11.9 million in Q2 2026 and bottomed at $4.9 million in Q2 2024.
• Historically, Research & Development has averaged $8.3 million across 3 years, with a median of $7.9 million in 2025.
• The widest YoY moves for Research & Development: up 69.42% in 2025, down 45.12% in 2025.
• Over 3 years, Research & Development stood at $6.4 million in 2024, then jumped by 69.42% to $10.8 million in 2025, then increased by 10.28% to $11.9 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $11.9 million, $10.3 million, and $10.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.